-
1Academic Journal
المؤلفون: Boyd, Anders, Moh, Raoul, Maylin, Sarah, Chekaraou, Mariama, Abdou, Mahjoub, Nadia, Gabillard, Delphine, Anglaret, Xavier, Paul Eholié, Serge, Delaugerre, Constance, Danel, Christine, Zoulim, Fabien, Lacombe, Karine
المساهمون: Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Programme PAC-CI, ANRS France Recherche Nord & sud Sida-hiv hépatites, Université Félix Houphouët-Boigny Abidjan, Côte d'Ivoire (UFHB), Laboratoire de Virologie CHU Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
المصدر: ISSN: 1352-0504.
مصطلحات موضوعية: basal core promotor, precore, antiviral treatment, genetic variability, immunosuppression, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
-
2Dissertation/ Thesis
المؤلفون: Pivert, Adeline
Thesis Advisors: Angers, Casefont-Ducancelle, Alexandra, Lunel-Fabiani, Françoise
-
3Dissertation/ Thesis
المؤلفون: Pivert, Adeline
المساهمون: Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Université d'Angers, Alexandra Casefont-Ducancelle, Françoise Lunel-Fabiani
المصدر: https://theses.hal.science/tel-02191498 ; Médecine humaine et pathologie. Université d'Angers, 2017. Français. ⟨NNT : 2017ANGE0075⟩.
مصطلحات موضوعية: Hepatitis B virus, Basal core promotor and precore mutations, Lentiviral technology, HepaRG, Liver fibrosis, Virus de l’hépatite B, Mutations du promoteur basal du core et precore, Technologie lentivirale, Fibrose hépatique, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Relation: NNT: 2017ANGE0075; tel-02191498; https://theses.hal.science/tel-02191498; https://theses.hal.science/tel-02191498/document; https://theses.hal.science/tel-02191498/file/PIVERT.pdf
-
4Dissertation/ Thesis
المؤلفون: Pivert, Adeline
المساهمون: Angers, Casefont-Ducancelle, Alexandra, Lunel-Fabiani, Françoise
-
5Academic Journal
المؤلفون: Croagh, Catherine Mn, Desmond, Paul V, Bell, Sally J
المصدر: World J Hepatol ; ISSN:1948-5182 ; Volume:7 ; Issue:3
مصطلحات موضوعية: Basal core promotor, Chronic hepatitis B, Genotype, Mutations, Pre-core
Relation: https://doi.org/10.4254/wjh.v7.i3.289; https://pubmed.ncbi.nlm.nih.gov/25848459; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381158/
-
6Dissertation/ Thesis
المؤلفون: 楊懷壹, Yang, Hwai-I
المساهمون: 陳建仁, 臺灣大學：流行病學研究所
مصطلحات موضوعية: B型肝炎病毒, 病毒因子, 肝細胞癌, 肝硬化, B型肝炎e抗原, B型肝炎病毒DNA, B型肝炎病毒量, B型肝炎病毒基因型, B型肝炎病毒突變, Precore, Basal Core Promoter, 風險預測模式, Hepatitis B Virus, Virus Factor, Liver Cirrhosis, Hepatocellular Carcinoma, Hepatitis B e Antigen, HBV DNA, Viral Load, HBV Genotype, HBV Mutants, Basal Core Promotor, Risk Prediction Model
وصف الملف: 1033198 bytes; application/pdf
Relation: 1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24):1733-1745. 2. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 Suppl:E3-E6. 3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61(10):1942-1956. 4. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, editor. Viral Hepatitis: Diagnosis, Treatment, Prevention. New York: Marcel Deckker; 1997 p. 315-330. 5. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 2002; 36(5):1046-1049. 6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34(6):1225-1241. 7. Beasley RP. Hepatitis B virus as the etiological agent in hepatocellular carcinoma: epidemiological consideration. Hepatology 1982; 2:21-26. 8. Chen CJ, Lu SN, You SL et al. [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. J Formos Med Assoc 1995; 94 Suppl 2:S94-102. 9. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262(5132):369-370. 10. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997; 12(9-10):S218-S222. 11. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2(8256):1129-1133. 12. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12(9-10):S294-S308. 13. Hepatitis viruses. Lyons, France: International Agency for Research on Cancer; 1994. 14. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29(3):971-975. 15. Farrell G. Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000; 61(3):374-379. 16. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984; 13(4):385-391. 17. Chu CM, Liaw YF, Sheen IS, Lin DY, Huang MJ. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology 1983; 3(6):947-950. 18. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51(20):5621-5625. 19. Lu SN, Lin TM, Chen CJ et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62(9):2051-2055. 20. Lin TM, Chen CJ, Lu SN et al. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res 1991; 11(6):2063-2065. 21. Chen CJ, Liang KY, Chang AS et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13(3):398-406. 22. Tsai JF, Jeng JE, Ho MS et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73(12):1498-1502. 23. Pena E, Rohatgi VK. Small sample and efficiency results for the Nelson-Aalen estimator. J Statist Plann Inference 1993; 37:192-202. 24. Breslow N, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Statist 1974; 2:437-453. 25. Aalen O. Nonparametric Inference for A Family of Counting Processes. Ann Statist 1978; 6(4):701-726. 26. Heyward WL, Bender TR, Lanier AP, Francis DP, McMahon BJ, Maynard JE. Serological markers of hepatitis B virus and alpha-fetoprotein levels preceding primary hepatocellular carcinoma in Alaskan Eskimos. Lancet 1982; 2(8304):889-891. 27. Kew MC. Hepatitis viruses and hepatocellular carcinoma. Res Virol 1998; 149(5):257-262. 28. Chisari FV, Klopchin K, Moriyama T et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59(6):1145-1156. 29. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54:665-697. 30. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47(5):412-426. 31. Shafritz DA, Kew MC. Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas. Hepatology 1981; 1(1):1-8. 32. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 7(3):243-260. 33. Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987; 84(3):866-870. 34. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351(6324):317-320. 35. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21(2):313-321. 36. Henkler FF, Koshy R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat 1996; 3(3):109-121. 37. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8(5):1109-1117. 38. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995; 55(24):6012-6016. 39. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334(22):1422-1427. 40. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347(3):168-174. 41. Chen CJ, Yang HI, You SL. Hepatitis B e antigen and the risk of hepatocellular carcinoma (authors reply). N Engl J Med 2002; 347(21):1722. 42. You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med 2004; 36(3):215-224. 43. Geier A, Dietrich CG, Gartung C. Antiviral therapy in HBe-Ag-positive hepatitis B with normal aminotransferase levels. Hepatology 2003; 37(3):712-713. 44. Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18(3):239-245. 45. Lok ASF, Dietrich CG, Gartung C. Antiviral therapy in HBe-Ag-positive hepatitis B with normal aminotransferase levels (reply). Hepatology 2003; 37(3):713. 46. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37(6):1309-1319. 47. Alberti A. Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? Hepatology 2003; 38(1):18-20. 48. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36(6):1408-1415. 49. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995; 22(5):1387-1392. 50. Lee PI, Chang MH, Lee CY et al. Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 1990; 12(4 Pt 1):657-660. 51. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32(3):294-298. 52. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35(6):1522-1527. 53. Huo T, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000; 12(6):687-693. 54. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8(3):493-496. 55. Yu MW, Hsu FC, Sheen IS et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145(11):1039-1047. 56. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21(4):656-666. 57. Tamura I, Kurimura O, Koda T et al. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. J Gastroenterol Hepatol 1993; 8(5):433-436. 58. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97(11):2886-2895. 59. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21(1):77-82. 60. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103(5):1630-1635. 61. Andreone P, Gramenzi A, Cursaro C et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004; 11(5):439-442. 62. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26(5):1338-1342. 63. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351(15):1521-1531. 64. Di M, V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40(4):883-891. 65. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21(5):303-308. 66. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97(4):265-272. 67. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150(5):1051-1054. 68. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135(9):759-768. 69. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15 Suppl:E20-E24. 70. Liaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7(1):1-3. 71. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105(4):1141-1151. 72. Moreno-Otero R, Garcia-Monzon C, Garcia-Sanchez A, Garcia BL, Pajares JM, Di Bisceglie AM. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol 1991; 86(5):560-564. 73. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120(7):1828-1853. 74. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39(3):857-861. 75. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118(3):554-559. 76. Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol 2002; 40(1):22-25. 77. Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73 ( Pt 5):1201-1208. 78. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83(Pt 8):2059-2073. 79. Orito E, Ichida T, Sakugawa H et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34(3):590-594. 80. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122(7):1756-1762. 81. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37(1):19-26. 82. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40(4):1207-1209. 83. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33(6):998-1002. 84. Rokuhara A, Kiyosawa K. Hepatitis B virus: mutations in the precore/basal core promoter and viral replication. J Gastroenterol 2002; 37(4):318-320. 85. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31(5):1037-1044. 86. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25-137. 87. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001; 34(2):432-435. 88. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2(8663):588-591. 89. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324(24):1699-1704. 90. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324(24):1705-1709. 91. Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88(10):4186-4190. 92. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68(12):8102-8110. 93. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70(9):5845-5851. 94. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33(1):218-223. 95. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124(2):327-334. 96. Lin CL, Liao LY, Wang CS et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25(3):564-570. 97. Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193(9):1258-1265. 98. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005; 12(5):456-464. 99. Yeh SH, Tsai CY, Kao JH et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41(4):659-666. 100. Chang C, Enders G, Sprengel R, Peters N, Varmus HE, Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 1987; 61(10):3322-3325. 101. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87(17):6599-6603. 102. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160(4):2013-2021. 103. Hasegawa K, Huang JK, Wands JR, Obata H, Liang TJ. Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. Virology 1991; 185(1):460-463. 104. Lindh M, Horal P, Dhillon AP, Furuta Y, Norkrans G. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 1996; 24(3):494-501. 105. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 1997; 4(1):1-8. 106. Takahashi K, Aoyama K, Ohno N et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76 ( Pt 12):3159-3164. 107. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233(2):374-381. 108. Tang H, Raney AK, McLachlan A. Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol 2001; 75(19):8937-8948. 109. Yu X, Mertz JE. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J Virol 2003; 77(4):2489-2499. 110. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98(10):2268-2276. 111. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. Journal of Virology 1999; 73(2):1239-1244. 112. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29(3):946-953. 113. Kidd-Ljunggren K, Oberg M, Kidd AH. The hepatitis B virus X gene: analysis of functional domain variation and gene phylogeny using multiple sequences. J Gen Virol 1995; 76 ( Pt 9):2119-2130. 114. Koike K. Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology 1995; 38(3-4):134-142. 115. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18(34):4848-4859. 116. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97(2):406-412. 117. Sung JJ, Chan HL, Wong ML et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9(3):229-234. 118. Parekh S, Zoulim F, Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77(12):6601-6612. 119. Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B Virus e Antigen Variants. Int J Med Sci 2005; 2(1):2-7. 120. Khan N, Guarnieri M, Ahn SH et al. Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 2004; 78(7):3262-3270. 121. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72(3):363-369. 122. Yuen MF, Tanaka Y, Mizokami M et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25(9):1593-1598. 123. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12(2):111-124. 124. Yu MW, Cheng SW, Lin MW et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000; 92(24):2023-2028. 125. Yu MW, Yang YC, Yang SY et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001; 93(21):1644-1651. 126. Yu MW, Yang YC, Yang SY et al. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. Hepatology 2002; 36(1):156-163. 127. Yeh SH, Chang CF, Shau WY et al. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 2002; 62(15):4346-4351. 128. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25 Suppl 1:40-47. 129. McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. CMAJ 1997; 157(4):422-428. 130. Kalbfleish J, Prentice R. The statistical analysis of failure time data. New York, NY: John Wiley and Sons; 1980. 131. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15(4):361-387.; en-US; http://ntur.lib.ntu.edu.tw/handle/246246/56209; http://ntur.lib.ntu.edu.tw/bitstream/246246/56209/1/ntu-95-F87842002-1.pdf